C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/00 (2006.01) A61K 39/395 (2006.01) A61P 37/02 (2006.01) C07K 16/46 (2006.01) C07K 16/28 (2006.01)
Patent
CA 2688490
IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
L'invention concerne des composés de remplacement d'IVIG dérivés d'une création recombinante et/ou biochimique de substances biomimétiques immunologiquement actives. Ces composés de remplacement sont ensuite criblés in vitro pour évaluer l'efficacité de chaque composé de remplacement en ce qui concerne la modulation de la fonction immunitaire. Des composés de remplacement particuliers sont sélectionnés pour une validation et une optimisation posologie/administration in vivo supplémentaires. Enfin, les composés de remplacement sont utilisés pour traiter les larges gammes de maladies, y compris des maladies inflammatoires et auto-immunitaires.
Block David S.
Schulze Dan H.
Strome Scott E.
Deeth Williams Wall Llp
Gliknik Inc
University Of Maryland Baltimore
LandOfFree
Immunoglobulin constant region fc receptor binding agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoglobulin constant region fc receptor binding agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoglobulin constant region fc receptor binding agents will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1446618